Veru Reports First Quarter Fiscal 2022 Results as US FC2 Prescription Net Revenues Climb 27%

09.02.2022 - -FC2 Prescription Business Entering 6th Year of Growth - -FDA Approves Company’s ENTADFI, New Treatment for Benign Prostatic Hyperplasia with Commercialization Plans Underway- -Company Enters into Clinical Trial ...

Related Keywords

Brazil ,Miami ,Florida ,United States ,Mexico ,Bulgaria ,Colombia ,Argentina ,America ,Mitchell Steiner ,Samuel Fisch ,Enobosarm Monotherapy ,Eli Lilly ,Sexual Health Division ,Sexual Health Business ,Nasdaq ,Company To Host Investor Conference Call ,Exchange Commission ,Company Form ,Registration Program Receives ,Corporate Communications ,Breast Cancer Program ,Prostate Cancer Program ,Veru Inc ,Goodrx Inc ,Company Enters ,Clinical Trial Collaboration ,Supply Agreement ,Evaluate Enobosarm ,Abemaciclib Combination ,Metastatic Breast Cancer ,Program Receives ,Track Designation ,Clinical Results Expected ,First Half ,Host Investor Conference Call Today ,Quarter Financial Summary ,Chief Executive Officer ,Fast Track ,Pipeline Highlights ,High Risk ,Acute Respiratory Distress Syndrome ,Clinical Improvement ,Line Treatment ,Breast Cancerwith ,Novel Oral Cytoskeleton Disruptor Agent ,Breast Cancer ,Combination Therapy ,Enobosarm Combination Therapy ,Metastatic Triple Negative Breast Cancer Patients ,Progressed After Receiving ,Least Two Systemic ,Planned Phase ,Metastatic Castration ,Antagonist Peptide ,Month Subcutaneous Depot Formulation ,Androgen Deprivation Therapy ,Advanced Prostate Cancer ,Benign Prostatic Hyperplasia ,Private Securities Litigation Reform Act ,Consolidated Statements ,Months Ended December ,Media Contact ,Investor Relations ,